25 North 38th Street
11th Floor
Philadelphia, PA 19104
United States
267 817 5790
https://www.centurytx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 152
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Brent Pfeiffenberger M.B.A., Pharm.D. | CEO & Director | 274,06k | S.O. | S.O. |
Dr. Adrienne Farid Ph.D. | COO & Head of Early Development | 670,29k | S.O. | 1962 |
Dr. Gregory Russotti Ph.D. | Chief Technology & Manufacturing Officer | 852,56k | S.O. | 1967 |
Mr. Kenneth J. Dow J.D. | Senior VP of General Counsel | S.O. | S.O. | S.O. |
Dr. Shane Williams Ph.D. | Chief People Officer | S.O. | S.O. | S.O. |
Dr. Hyam I. Levitsky M.D. | President of Research & Development | 502,12k | S.O. | 1958 |
Michael Naso Ph.D. | Senior VP of Cell Engineering | S.O. | S.O. | S.O. |
Dr. Nick Trede M.D., Ph.D. | Senior VP & Head of Clinical Development | S.O. | S.O. | S.O. |
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
L’ISS Governance QualityScore de Century Therapeutics, Inc. en date du 1 mai 2024 est 7. Les scores principaux sont Audit : 8; Société : 5; Droits des actionnaires : 8; Compensation : 8.